ACET Strangle Strategy

ACET (Adicet Bio, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.

ACET (Adicet Bio, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $78.2M, a beta of 1.59 versus the broader market, a 52-week range of 6.01-17.44, average daily share volume of 114K, a public-listing history dating back to 2018, approximately 152 full-time employees. These structural characteristics shape how ACET stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.59 indicates ACET has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a strangle on ACET?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current ACET snapshot

As of June 30, 2026, spot at $8.73, ATM IV 289.40%, IV rank 56.71%, expected move 82.97%. The strangle on ACET below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.

Why this strangle structure on ACET specifically: ACET IV at 289.40% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 82.97% (roughly $7.24 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ACET expiries trade a higher absolute premium for lower per-day decay. Position sizing on ACET should anchor to the underlying notional of $8.73 per share and to the trader's directional view on ACET stock.

ACET strangle setup

The ACET strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ACET near $8.73, the first option leg uses a $9.17 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ACET chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ACET shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$9.17	N/A
Buy 1	Put	$8.29	N/A

ACET strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

ACET strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on ACET. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on ACET

Strangles on ACET are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ACET chain.

ACET thesis for this strangle

The market-implied 1-standard-deviation range for ACET extends from approximately $1.49 on the downside to $15.97 on the upside. A ACET long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ACET IV rank near 56.71% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on ACET should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ACET options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ACET-specific events.

ACET strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ACET positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ACET alongside the broader basket even when ACET-specific fundamentals are unchanged. Always rebuild the position from current ACET chain quotes before placing a trade.

Frequently asked questions

What is a strangle on ACET?: A strangle on ACET is the strangle strategy applied to ACET (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ACET stock trading near $8.73, the strikes shown on this page are snapped to the nearest listed ACET chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are ACET strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ACET strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 289.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ACET strangle?: The breakeven for the ACET strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ACET market-implied 1-standard-deviation expected move is approximately 82.97%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on ACET?: Strangles on ACET are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ACET chain.
How does current ACET implied volatility affect this strangle?: ACET ATM IV is at 289.40% with IV rank near 56.71%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.